Drug intelligence / Profile preview

CAR-22

Development stage: Preclinical
Lead developer: Stanford University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CAR-22 is a preclinical cell therapy being co-developed by BioCardia and AstraZeneca for regenerative therapies in cardiovascular disorders. This investigational therapy is designed to utilize BioCardia's Helix™ biotherapeutic delivery catheter for enhanced delivery efficiency. As a CAR-based cell therapy, it involves engineering cells with a Chimeric Antigen Receptor (CAR) to target specific antigens, aiming to promote regeneration and repair in the cardiovascular system.

Targets

CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on CAR-22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-22.

Explore the full profile